LRMR SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 19, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 30, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWLarimar Therapeutics Completes Rolling BLA Submission for Nomlabofusp in Friedreich’s Ataxia

Nov 9, 2026

8-K

Larimar Therapeutics Appoints John B. Harlow, Jr. as President and Chief Operating Officer

Sep 29, 2026

8-K

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

Aug 4, 2026

8-K

Larimar Therapeutics Submits First Module of Rolling BLA for Nomlabofusp and Reports Positive Long-Term Data in Friedreich’s Ataxia

Jun 29, 2026

8-K

Larimar Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 19, 2026

8-K

Larimar Therapeutics Reports Q1 2026 Financial Results and Progress Toward Nomlabofusp BLA Submission

May 14, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Feb 26, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $75,000,000 | Bank: J.P. Morgan, Guggenheim Securities

Feb 25, 2026

424B5

REGISTERED OFFERING

Jul 30, 2025

424B5

SHELF OFFERING | Warrants exercise price: $2.64 | Bank: Leerink Partners, Guggenheim Securities

Jul 29, 2025

424B5

SHELF OFFERING | Shares amount: 17,162,472 | Share price: $8.74 | Offering amount: $150,000,005.00

Feb 14, 2024

424B5

PENDING OFFERING | PENDING OFFERING | Share price: $7.831

Feb 13, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 19, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 24, 2025

S-3

SHELF | ATM | Offering amount: $300,000,000.00 EFFECTIVE

May 9, 2024

S-8

Registration

Mar 14, 2024

S-8

Registration

Mar 14, 2024

S-8

Registration

Mar 14, 2023

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Harlow John B. Jr. (Reporting)

Oct 1, 2026

Harlow John B. Jr. (Reporting)

Oct 1, 2026

Hamilton Thomas Edward (Reporting)

Jul 8, 2026

DEERFIELD MANAGEMENT COMPANY, L.P. (Reporting)

May 20, 2026

LEFF JONATHAN S (Reporting)

May 20, 2026

SHERMAN JEFFREY W (Reporting)

May 20, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 28, 2024

CORRESP

Form CORRESP - Correspondence

May 22, 2024

LETTER

Form UPLOAD - SEC-generated letter

May 16, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 22, 2022

CORRESP

Form CORRESP - Correspondence

Nov 18, 2022

LETTER

Form UPLOAD - SEC-generated letter

Nov 16, 2022

Larimar Therapeutics, Inc. LRMR · SEC Filings